Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Immuron posts record FY26 revenue; key assets advance with FDA IND

Aug 28, 2026, 6:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong FY26 results and explicit near-term milestones (IND approval, EoP2 potential, DoD collaboration) typically lift biotech names on progress. Positive guidance for 2027 NA expansion adds optionality, though execution risk remains high for early-stage assets.

AI summary

What happened, with direct paths to the underlying reporting

Immuron reported record FY26 revenue of A$7.7 million, with net profit up and cash at A$9.0 million. Growth occurred in Australia, the US, and Canada, with US sales rising 13% in USD terms and Canada more than doubling in H2. Milestones include FDA IND approval for IMM-529 and ongoing development/partnership progress for IMM-124E and IMM-529, setting a foundation for North American expansion in FY27.

FY26 revenue record at A$7.7m; net profit up A$1.4m.
Australia Travelan +10%; US USD sales +13% YoY.
Canada >100% growth in 2H FY26; overall cash A$9.0m.
IND for IMM-529 approved Nov 2025; IMM-124E Phase 2 potential.
FY27 focuses on North America expansion; Q1 Travelan growth, Q3 IMM-529 partnering.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.